T1	Participants 40 67	human platelet aggregation.
T2	Participants 443 516	40 aspirin-na√Øve volunteers with at least one cardiovascular risk factor
T3	Participants 612 715	from 20 patients with a prior diagnosis of coronary heart disease who were chronically assuming aspirin
